Publication: 2

Publication: 2

Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Am J Clin Oncol vol 35 (4) 329-333

Year:: 2012
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 1

Parents:: 400 404
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: U10 CA035267, N01 CA035431, CA-37404, CA-35090, CA-35195, U10 CA037404, U10 CA035195, CA-25224, U10 CA037404-21, U10 CA035431, U10 CA025224, U10 CA035090, CA-35267, U10 CA025224-26

Corr. Author:
Authors:: Steven R. Alberts Tom R. Fitch George P. Kim Bruce W. Morlan Shaker R. Dakhil Howard M. Gross Suresh Nair

Networks:

Study: NCCTG-N044J
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: AZD2171, cediranib, hepatocellular carcinoma, phase II, VEGF